# Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc. is a company headquartered in Hamilton, Canada.

## Company overview

- **Legal name:** Fusion Pharmaceuticals Inc.
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Hamilton, Canada
- **Incorporated in:** Z4
- **Fiscal year end:** December 31
- **SEC CIK:** 0001805890

## About

Fusion Pharmaceuticals Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001805890, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2024-03-20, it reported annual revenue of USD 2,068,000; net income of USD -94,897,000; total assets of USD 285,836,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $2.1M (USD 2,068,000)
- **Net income:** -$94.9M (USD -94,897,000)
- **Total assets:** $285.8M (USD 285,836,000)
- **Cash and equivalents:** $61.5M (USD 61,456,000)
- **Operating cash flow:** -$81.8M (USD -81,802,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $1.5M (USD 1,461,000)
- **Net income:** -$87.6M (USD -87,612,000)
- **Total assets:** $219.1M (USD 219,064,000)
- **Cash and equivalents:** $43.9M (USD 43,861,000)
- **Operating cash flow:** -$73.3M (USD -73,276,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $1.4M (USD 1,440,000)
- **Net income:** -$81.0M (USD -81,047,000)
- **Total assets:** $252.3M (USD 252,271,000)
- **Cash and equivalents:** $52.9M (USD 52,898,000)
- **Operating cash flow:** -$75.7M (USD -75,740,000)

### FY2020 (period ended 2020-12-31)

- **Net income:** -$78.3M (USD -78,333,000)
- **Total assets:** $310.7M (USD 310,676,000)
- **Cash and equivalents:** $90.5M (USD 90,517,000)
- **Operating cash flow:** -$29.8M (USD -29,767,000)

## Recent SEC filings

- Form 8-K — filed 2024-06-04 — period 2024-06-04 — 8-K
- Form 8-K — filed 2024-05-31 — period 2024-05-31 — 8-K
- Form 8-K — filed 2024-05-29 — period 2024-05-29 — 8-K
- Form 8-K — filed 2024-05-10 — period 2024-05-10 — 8-K
- Form 10-Q — filed 2024-05-07 — period 2024-03-31 — 10-Q
- Form 8-K — filed 2024-05-07 — period 2024-05-07 — 8-K
- Form 8-K — filed 2024-05-02 — period 2024-04-30 — 8-K
- Form 8-K — filed 2024-04-23 — period 2024-04-22 — 8-K
- Form 10-K/A — filed 2024-04-12 — period 2023-12-31 — 10-K/A
- Form 8-K — filed 2024-04-09 — period 2024-04-09 — 8-K
- Form SC 13D — filed 2024-03-25
- Form 10-K — filed 2024-03-20 — period 2023-12-31 — 10-K

---

Updated: 2026-10-23T19:32:55Z

Canonical page: https://altss.com/profile/fusion-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology